Shares of Puma Biotechnology Inc (NYSE:PBYI) have been assigned an average recommendation of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $101.31.

Several brokerages have weighed in on PBYI. Bank of America Corporation reissued a “buy” rating and set a $117.00 price objective (up from $100.00) on shares of Puma Biotechnology in a report on Friday. Leerink Swann reissued an “outperform” rating and set a $125.00 price objective (up from $115.00) on shares of Puma Biotechnology in a report on Wednesday. Citigroup Inc. reissued a “buy” rating and set a $114.00 price objective on shares of Puma Biotechnology in a report on Tuesday. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Puma Biotechnology in a research note on Tuesday. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $118.00 price target (up from $90.00) on shares of Puma Biotechnology in a research note on Tuesday.

In related news, SVP Richard Paul Bryce sold 5,000 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $87.10, for a total value of $435,500.00. Following the transaction, the senior vice president now owns 34,237 shares in the company, valued at $2,982,042.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of the firm’s stock in a transaction on Friday, May 26th. The stock was sold at an average price of $75.38, for a total value of $93,147,066.00. The disclosure for this sale can be found here. In the last three months, insiders sold 1,995,088 shares of company stock valued at $157,988,613. 22.70% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Montreal Can bought a new position in shares of Puma Biotechnology during the first quarter worth approximately $195,000. Alambic Investment Management L.P. bought a new position in shares of Puma Biotechnology during the first quarter worth approximately $201,000. Fox Run Management L.L.C. bought a new position in shares of Puma Biotechnology during the second quarter worth approximately $227,000. Creative Planning boosted its position in shares of Puma Biotechnology by 62.3% in the second quarter. Creative Planning now owns 2,862 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 1,099 shares during the last quarter. Finally, Parametric Portfolio Associates LLC bought a new position in shares of Puma Biotechnology during the first quarter worth approximately $257,000. Institutional investors own 80.98% of the company’s stock.

Puma Biotechnology (PBYI) traded down 1.16% during trading on Friday, hitting $93.65. 502,329 shares of the stock traded hands. The stock’s market cap is $3.46 billion. The firm’s 50-day moving average is $84.95 and its 200 day moving average is $50.35. Puma Biotechnology has a 52 week low of $28.35 and a 52 week high of $97.15. Puma Biotechnology also was the recipient of unusually large options trading on Tuesday. Investors acquired 12,110 put options on the stock. This is an increase of 868% compared to the typical volume of 1,251 put options.

Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.06) by $0.09. Equities research analysts forecast that Puma Biotechnology will post ($8.43) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/21/puma-biotechnology-inc-nysepbyi-given-average-rating-of-buy-by-analysts.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.